AbbVie, Voyager sign $1.2bn agreement for anti-tau antibodies aimed at CNS diseases; deal later terminated
AbbVie Inc. and Voyager Therapeutics Inc. are teaming up in the development of vectorized tau antibodies for treating neurodegenerative conditions including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com